This article studies the determinants of pharmaceutical innovation diffusion among specialists. To this end, it investigates the influences of six categories of factors-social embeddedness, sociodemography, scientific orientation, prescribing patterns, practice characteristics, and patient panel composition-on the use of 11 new drugs for the treatment of type 2 diabetes mellitus in Hungary.
INTRODUCTION
The healthcare industry all over the world faces the challenge of providing high quality patient care in an environment of limited resources. Recent developments in analytics and information technology offer important data-driven opportunities for enhancing the delivery of healthcare. Healthcare institutions which analyse big data are performing better, with lower costs, higher quality of care, shorter waiting times, reductions in medical errors, higher reimbursement rates (Alemi 2005) . New drug diffusion is an area where healthcare analytics might result in better outcomes both for pharmaceutical companies and healthcare politicians. For this purpose, millions of prescription data should be mined and combined with doctors' characteristics, including their social network.
Innovation and the successful diffusion of new drugs are critical for the financial performance of pharmaceutical companies. Medicine and society benefit from pharmaceutical innovations as well (Greenhalgh 2005) . Where new drugs expand therapeutics in areas of yet unmet clinical need, patients benefit from the early access to the latest therapeutic innovations. Improved health status might result in higher employment rates. Furthermore, newly marketed drugs, if cost efficient, have high potential to drive improvements in healthcare from the limited healthcare budget: a better health status is either achieved from the same budget, or the health status of patients is maintained at a lower cost.
New drug uptake might be either driven by external forces, such as regulation, characteristics of medicines, competition, marketing effort or by internal forces such as social contagion (Dunn et al. 2012 ). The diffusion of pharmaceutical innovation is mainly determined by the behaviour of patients and medical professionals, as well as the strategies of pharmaceutical companies and government policies (e. g. Greenhalgh 2005; Lublóy 2014; Coleman et al. 1966; Iyengar et al. 2011) . Although doctors consider new drugs on individual merits, some may be more predisposed to adopt one than others. Several factors, such as participation in clinical trials, prescribing volume, either in total or 3 within the therapeutic class of the new drug, pharmaceutical companies' marketing efforts and some patient characteristics are significantly associated with early adoption (Lublóy 2014) . Furthermore, several studies found convincing empirical evidence of social contagion in new drug diffusion (e. g. Coleman et al. 1966; Iyengar et al. 2011; Lin et al. 2011; Liu -Gupta 2012; Manchanda et al. 2008 ).
Social interactions among colleagues are indispensable to gaining knowledge and reducing uncertainty about the consequences of new drug adoption.
Previous literature on social contagion classified physicians according to the roles that they played in their social networks such as advisors, discussion partners, friends, physicians to whom patients are referred, and colleagues similar in terms of age and tenure (e.g. Lin et al. 2011; Liu -Gupta 2012; Manchanda et al. 2008; Van den Bulte C -Lilien 2001) . Prior research used surveys and mail questionnaires for identifying early adopters and for listing collegial interactions (Chauhan -Mason 2008; Mason 2008) . A retrospective study based on self-reporting is not only costly, but runs the risks of recall and social desirability bias. This article uses prescription data which reflect prescribing realities, and thus are exempt from recall bias, and follows an alternative approach to defining social networks. Instead of asking specialists to list their collegial interactions, this article mines databases to construct the contagion measures. The contagion measures, being exempt from social desirability bias, reflect distinct channels of interpersonal communication: with former classmates, scientific collaborators, and geographically close colleagues.
This article contributes to the literature on social contagion in new drug diffusion in the age of analytics, as large-scale prescription data and contagion measures extracted from databases. We investigate whether social contagion measures extracted from databases rather than from survey and mail questioners support pharmaceutical companies and healthcare politicians in influencing the uptake of pharmaceutical innovations. We hypothesize that the higher the number of classmates, coauthors and geographically close colleagues who have already adopted the new drug, the higher the likelihood of adoption by a specific physician.
The influences of former classmates and scientific collaborators on new drug diffusion have never been analysed in the pharmaceutical literature before. However, empirical evidence shows that former classmates are important channels of knowledge diffusion in various areas of life (Dahl -Pedersen 2004; Østergaard 2009) . Furthermore, anecdotal evidence shows that physicians regularly exchange ideas with former classmates even after graduation, especially if they practice medicine in the same specialty (Bajaj 2015; Wong 2015) . Similarly, the influential role of scientific collaborators was 4 proved in many other domains (Acedo et al. 2006; Glänzel -Schubert 2005) . Although distancebased contagion measures were used in two recent studies (Liu -Gupta 2012; Manchanda et al. 2008) , the pharmaceutical literature calls for further research on this measure.
If contagion measures extracted from databases are found to be important predictors of new drug uptake, then pharmaceutical companies and health politicians might rely upon these contagion measures to influence new drug diffusion, and target their interventions at doctors whose adoption is the most contagious. For pharmaceutical companies, personal selling through sales representatives, is the primary promotional instrument (Manchanda -Honka 2005) , and thus knowing the key-opinion leaders in the overlapping social networks is of major importance (Greenhalgh 2005) . Governments are major influencers of new drug uptake through regulatory and approval agencies and budgetary allocations. However, healthcare politicians might encourage the adoption of the most efficient/least expensive new drugs through continuing medical education-targeting relevant, tailored information at specialist subgroups whose behaviour is contagious.
Following this introduction, section 2 presents the key characteristics of the study drugs and the data sources used, discusses the statistical model, and specifies the covariates. Section 3 presents the results, which are then discussed in section 4, alongside policy implications and several possible research limitations. Finally, section 5 summarizes the research findings.
METHODS

Study Drugs
This article focuses on new anti-diabetic drugs (A10Bs) for the treatment of type 2 diabetes mellitus Table 1 . When added to metformin, the default treatment for T2DM, each drug reduces the HbAc1 level, with close to equal efficiencies, and despite distinct modes of action (EMA 2015) .
The study drugs are prescribed by internists subspecialized in endocrinology-a fairly closed community, suitable for the purpose of this article. In Hungary, specialists share the care of T2DM patients with general practitioners, allowing for the examination of routine-as opposed to just firsttime-adoption of new A10Bs. Adoption becomes routine when specialists first ask referring general practitioners to prescribe new A10Bs, on grounds of efficacy and efficiency. Intuitively, any such drugs are already part of the specialists' prescribing portfolios, following first-time adoption and follow-up tests. contribute to constructing the scientific collaboration network.
Statistical Model
Similarly to many recent studies of the fields (Iyengar et al. 2011; Lin et al. 2011; Wen et al. 2011), this article uses the Cox proportional hazards model (Cox 1972) to examine factors influencing the likelihoods of routine adoptions of A10Bs by specialists. The Cox model is the most appropriate choice for the purpose because of the way it handles right-censored data-cases where specialists had not routinely adopted the A10Bs by the end of 2011 (time t). The model specified in Equation 1
h(t | Z, x(t))relates the time that passes before initial adoption to covariates that may be associated with that quantity of time. Separate models were run for each social contagion measure. The time period was divided into K equal parts by determining (K-1) points in time (0 < 1 = 30 < 2 = 7 60 < ⋯ < −1 ).
The hazard ratio/likelihood of routine adoption at time t for each specialist is specified in Equation 1 as follows: The dependent variable is a dummy indicating each month whether the specialist had routinely adopted the A10B.
Independent Variables
In the literature, interactions-professional and social-appear to be a very important influencing factor, information relayed through direct, personal contacts proving particularly powerful.
Physicians' adopting behaviours are affected by other physicians' knowledge, attitudes, and 8 behaviours, thus reducing safety and efficacy uncertainties (Lublóy 2014 , Coleman et al. 1966 Iyengar et al. 2011; Lin et al. 2011; Liu -Gupta 2012; Manchanda et al. 2008; McGettigan et al. 2001; Prosser -Walley 2006) . While other sources of information provide the nurturing groundwork of necessary knowledge, behavioural change requires the legitimizing power of personal advice from informed and respected colleagues through reliable, easy-to-digest assessments of new drugs.
In this article, contagion measures assess whether the adoption decisions of colleagues significantly influence specialists' likelihoods of adoption. Most prior research used surveys and mail questionnaires for constructing contagion measures (studies found convincing empirical evidence of social contagion in new drug diffusion (e. g. Coleman et al. 1966; Iyengar et al. 2011; Lin et al. 2011 ).
Survey-based contagion measures capture interpersonal effects directly, but are time consuming and costly. Furthermore, a retrospective study based on self-report is at risk of recall and social desirability time-dependent covariates, the latter were lagged by one month. Table 2 summarizes the descriptive statistics for the three contagion measures. Former classmates graduated from the same medical establishment in the same year, scientific collaborators either published an article or prepared a presentation together, and geographically close colleagues had offices within a pre-specified radius. As argued in the literature, a radius of 20 miles is long enough to capture most of the interpersonal effects and short enough to allow social network differentiations (Manchanda et al. 2008 ). This article defines specialists' spatial social networks through geographic circles with radiuses of 35 kilometres/22 miles centred on the specialists' practice locations, radius sensitivity double-checked by additional radiuses at ±20 per cent. Source: authors.
Control Variables
Without controlling for factors relevant to prescribing behaviour, empirical evidence is at risk of presenting confounding effects. This article controls for five categories of factors-physicians' sociodemographics, scientific orientations, prescribing patterns, as well as practice characteristics and patient-related factors. A systematic review on the determinants of new drug diffusion provides guidance for the control variables considered here and their expected signs (Lublóy 2014) . Control variables were considered only if either prior research or industry experts suggested that they may be associated with early adoption. Table 3 provides an overview of the 17 control variables. Source: authors.
RESULTS
The 318 physicians analysed here accounted for roughly 80 per cent of the specialists who treated T2DM on a daily basis. They were 52 years old, on average, and 48 per cent were male (see Table 3 for The regression results for the independent variables for the 11 study drugs are shown in Table 4 . In the table exp(γ)s are shown-hazard ratios between two specialists when the values of the respective variables differ by one unit, all other covariates being held constant. Variables with exp(γ)s larger than one are associated with increased hazard-the higher the variable, the higher the hazard of the event. The regression results for the control variables for the 11 study drugs are shown in 13 † p<0.1; * p<0.05; ** p<0.001; *** p<0.0001
The table shows the values for exp(γ), the ratio of hazards. If exp(γ) is larger than one, then the probability of a specialist adopting the new antidiabetic drug increases if the value of the respective social contagion measure increases by one unit, all other covariates being held constant.
The social influence from colleagues within a 35-kilometer radius is a partially important predictor of new drug uptake-at the 95 per cent-confidence level the adoption ratio is positively associated with the likelihood of initial adoption for six brands. Counterintuitively, former classmates significantly delay the diffusion process for one brand and scientific collaborators for three brands.
Among the rest, exchanges within social networks do not influence significantly the likelihood of initial adoption.
At the 95 per cent-confidence level, two control variables produce consistent predictions of early adoption ( Table 5 ). The number of brands individual specialists prescribe is a very influential predictor of new drug uptake. The wider the prescribing portfolios, the earlier specialists initiate new therapies, for all 11 brands, whereas the ratio of prescriptions for insulin is significantly negatively associated for nine brands. The rest of the control variables do not produce consistent prediction of new drug uptake: they are never associated with the likelihood of initial adoption for more than three brands. The table shows the values for exp(β), the ratio of hazards. If exp(β) is larger than one, then the probability of a specialist adopting the new antidiabetic drug increases if the value of the covariate increases by one unit, all other covariates being held constant.
DISCUSSION AND POLICY IMPLICATIONS
The findings reveal that social contagion among geographically close colleagues is ambiguousgeographically close colleagues do not exert a significant influence on the initial adoption in around half of the cases, whereas they might do so in the other half. This finding contradicts prior research reporting that the estimated effect of social contagion among general practitioners in geographic proximity is positive and significant even after controlling for time trends and marketing efforts (Liu -Gupta 2012; Manchanda et al. 2008 ). However, prior research assessed only one innovative study drug which became widely accepted shortly after its introduction among highly penetrated general practitioners in a smaller and more closed geographic region. Most probably the efficiency of drug sales representatives, the novelty and overall acceptance of the new drug, the penetration of doctors, and the characteristics of the geographic region all play a role in whether contagion among geographically close colleagues is indeed in force.
Furthermore, this article finds no empirical evidence for the hypothesized influential roles of former classmates and scientific collaborators. In a few cases, these had even delayed diffusion. Although former classmates know each other personally, they tend to discuss professional matters irregularly and might not be tied equally strong. A few classmates might be very influential, whereas the majority of them are not. Even if scientific collaborators exchange ideas regularly, their networks are small, sparse, and temporal which evidently hinders the diffusion process. Moreover, scientific collaborators with distinct affiliations most likely exchange ideas via e-mail-written communication offers less opportunity for sharing experience about a newly introduced drug than oral communication.
In new drug diffusion data-driven social network analysis provides only limited practical benefits for pharmaceutical companies and healthcare politicians. Although it is easier and cheaper to construct the three social networks studied here than it is to construct survey-based networks, the added value is low-they do not help accelerating the diffusion process. Regardless how time consuming and costly survey-based contagion measures are, their construction is inevitable in exploiting the social influence among doctors in new drug diffusion. The role of data-driven analysis in new drug diffusion, however should not be underrated. Data-driven analysis plays a pivotal role in mining large-scale prescription claims databases. Vast empirical evidence shows that the higher the prescribing volume in total or in the therapeutic class of a new drug, the higher the likelihood of early adoption of that new drug (Lublóy 2014) . Thus, identifying doctors prescribing the most and having the largest potential of exerting influence on new drug uptake through peer pressure is of major importance which requires data-driven approaches.
This article has several possible limitations. First and foremost, prescription data is incomplete.
specialists' prescribing behaviours are monitored through the reported prescription data by general practitioners with whom specialists share patient care. Second, the marketing efforts of pharmaceutical companies targeted at physicians are not accounted for. Had we controlled for marketing efforts, we might have found social contagion among physicians in geographic proximity even less influential. Third, the contagion measure based on geographic proximity captures interpersonal effects indirectly-one cannot validate whether geographically close physicians exchange ideas regularly, if at all. Fourth, conclusions based on only one therapeutic class cannot be generalized-future research may incorporate multiple therapeutic classes.
CONCLUSIONS
This article investigated whether data-driven social network analysis might support pharmaceutical companies and healthcare politicians in influencing the uptake of innovations. Several hundred thousands of prescription data was combined with social network data extracted from administrative databases. The large-scale archival dataset of specialists' actual prescribing behaviours and the three contagion measures avoided several statistical biases usually related to retrospective surveys-for example, confounding bias, sample selection bias, and recall bias.
First, this article showed that social contagion among geographically close colleagues is ambiguousgeographically close colleagues do not exert significant influence on the initial adoption in around half of the cases, whereas they might do so in the other half. This finding contradicts prior research reporting that the adoption ratio of geographically close colleagues is significantly associated with the likelihood of initial adoption. Future research may examine which factors determine whether contagion among geographically close colleagues is indeed in force. Second, this article found no empirical evidence for social contagion among former classmates and scientific collaborators.
In sum, data-driven social network analysis is of limited use-contagion measures extracted from administrative and bibliographic databases do not support pharmaceutical companies and healthcare politicians in exerting influence on new drug uptake. In new drug diffusion, data-driven analysis should focus on mining large-scale prescription claim databases and identify doctors prescribing the most in the therapeutic class of the new drug. Doctors with higher prescribing volumes shall than be targeted by drug sales representatives once their social network is appropriately mapped.
